• Draeger Medical (Telford, Pennsylvania) said that the Draeger Fabius MRI anesthesia machine has received FDA clearance. This product is designed specifically to meet the requirements for the Magnetic Resonance Imaging (MRI) environment. The Fabius MRI is designed for use with 1.5T and 3.0T MRI systems. An integrated Teslameter provides an acoustic alarm if the Fabius MRI is positioned within a field strength greater than 40mTesla (400 Gauss). The Fabius MRI uses the same user interface as Draeger's Fabius GS, Fabius Tiro and Apollo machines, creating a uniform and consistent interface for the anesthesia provider wherever anesthesia is required. Draeger Medical makes products and system solutions which accompany the patient throughout the care process – emergency care, perioperative care, critical care or perinatal care – as well as in home mechanical ventilation.

• Invitrogen (Carlsbad, California) reported the launch of Dynabeads MAX Legionella, which enables a process for targeting and concentrating legionella from environmental water samples. The Dynabeads MAX Legionella provides a rapid and highly reliable sample preparation process, improving the method used, and result achieved, for the detection and quantification of legionella. Typical procedures for legionella surveillance involve complicated filtration and subsequent culture steps. The filters collect large quantities of other organisms that grow in culture along with legionella, requiring subsequent re-culturing of suspected legionella bacteria. In addition, many of the contaminating organisms can inhibit the growth of the legionella bacteria and produce false negatives. Dynabeads MAX Legionella uses magnetic Dynabeads with antibodies that attach to legionella and selectively isolate and concentrate the bacterium from the sample, eliminating contaminating microorganisms. Invitrogen makes science technologies for research, production and diagnostics.

• Mellanox Technologies (Santa Clara, California) said that its InfiniBand adapters accelerate Toshiba Medical's AquilionONE, a new dynamic volume computed tomography system which significantly shortens patient diagnosis time, by enabling diagnosis of figure, dynamic image and function within a single scan, decreasing the need for multiple, duplicative tests and invasive procedures. The AquilionONE acquires large volumes of thin-slice, high-resolution data which can be rendered by advanced 3-D volume and vessel visualization software to streamline image interpretation. Mellanox InfiniBand adapters provide high bandwidth and low latency to keep overhead away from the processor, allowing more CPUs to be used for the visualization process. Mellanox Technologies makes semiconductor-based InfiniBand and Ethernet connectivity products that facilitate data transmission between servers, communications infrastructure equipment and storage systems.

• VisEn Medical (Bedford, Massachusetts) reported the commercial launch of its IntegriSense fluorescence in vivo imaging agent product line. The agent is the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration, and will enable researchers to image and assess the role of integrin alpha v beta 3 in disease progression and therapeutic response in vivo. IntegriSense is an optimized in vivo fluorescence imaging agent targeting integrin alpha v beta 3, a key biomarker closely associated with disease-related vascularity and angiogenesis. The agent was developed to enable in vivo imaging of integrin alpha v beta 3 expression in order to measure and monitor aspects of disease progression and therapeutic response in disease states including oncology, cardiovascular disease, and bone disease. VisEn Medical specializes in in vivo imaging.